Literature DB >> 7418717

The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.

F A Wiesel, G Alfredsson, M Ehrnebo, G Sedvall.   

Abstract

The pharmacokinetics of sulpiride was studied in 6 healthy volunteers after intravenous and oral (tablets) administration of 100 mg. An open two- and in two subjects a three-compartment model was applied following intravenous administration. The average total distribution volume during the terminal slope was 2.72 +/- 0.66 l/kg and total systemic clearance was 415 +/- 84 ml/min. The serum half-life of the terminal slope following intravenous administration averaged 5.3 h (range 3.7--7.1 h) according to the two-compartment model. In two subjects the half-lives were 11.0 and 13.9 h when the three-compartment model was applied. Determinations of urinary excretion rates of unchanged sulpiride indicated a half-life of 7.15 h. Following intravenous administration, 70 +/- 9% of the dose was recovered unchanged in urine within 36 h; the mean renal clearance was 310 +/- 91 ml/min. Sulpiride was absorbed slowly, with peak concentrations appearing between 3 and 6 h after oral administration. The recovery of unchanged drug in urine following oral administration was 15 +/- 5% of the dose, with a mean renal clearance of 223 +/- 47 ml/min. The bioavailability determined from combined plasma and urine data was only 27 +/- 9%. The low bioavailability was probably due to incomplete absorption.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418717     DOI: 10.1007/bf00558453

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Spectrophotofluorometric method for quantitative determination of sulpiride in human plasma and urine.

Authors:  T Kleimola; O Leppänen; J Kanto; R Mäntylä; E Syvälahti
Journal:  Ann Clin Res       Date:  1976-04

2.  A double-blind comparison of sulpiride with chlorpromazine in chronic schizophrenia.

Authors:  M Toru; Y Shimazono; M Miyasaka; T Kokubo; Y Mori; T Nasu
Journal:  J Clin Pharmacol New Drugs       Date:  1972 May-Jun

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Some pharmacokinetic aspects of 5-(dimethylriazeno)-imidazole-4-carboxamide in the dog.

Authors:  T L Loo; B B Tanner; G E Housholder; B J Shepard
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

5.  Clinico-pharmacological studies of sulpiride.

Authors:  M Nishiura
Journal:  Curr Ther Res Clin Exp       Date:  1976-08

6.  Metabolism of sulpiride in man and rhesus monkeys.

Authors:  A R Imondi; A S Alam; J J Brennan; L M Hagerman
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-03

7.  Fluoride bioavailability after intravenous and oral administration: importance of renal clearance and urine flow.

Authors:  J Ekstrand; M Ehrnebo; L O Boréus
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

8.  Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detection.

Authors:  G Alfredsson; G Sedvall; F A Wiesel
Journal:  J Chromatogr       Date:  1979-10-11
  8 in total
  22 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Authors:  Joao N Dos Santos Pereira; Sina Tadjerpisheh; Manar Abu Abed; Ali R Saadatmand; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

Review 3.  A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 4.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

5.  Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers.

Authors:  C von Bahr; F A Wiesel; G Movin; P Eneroth; P Jansson; L Nilsson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Methylphenidate boosts choices of mental labor over leisure depending on striatal dopamine synthesis capacity.

Authors:  Lieke Hofmans; Danae Papadopetraki; Ruben van den Bosch; Jessica I Määttä; Monja I Froböse; Bram B Zandbelt; Andrew Westbrook; Robbert-Jan Verkes; Roshan Cools
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

7.  Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens.

Authors:  D M Lewis; H R Bond; S H Curry
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers.

Authors:  G R McClelland; S M Cooper; A J Pilgrim
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

9.  Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon.

Authors:  G A Lanfranchi; G Bazzocchi; L Marzio; M Campieri; C Brignola
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.

Authors:  N M Rupniak; G Kilpatrick; M D Hall; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.